| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.06.23 | Replimune Group Inc: Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting | 549 | GlobeNewswire (Europe) | Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no progression... ► Artikel lesen | |
| 03.06.23 | Sutro Biopharma, Inc.: Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1 | 567 | GlobeNewswire (Europe) | - Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating... ► Artikel lesen | |
| 03.06.23 | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) | 719 | GlobeNewswire (Europe) | - Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable... ► Artikel lesen | |
| 03.06.23 | NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 | 627 | GlobeNewswire (Europe) | - Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate... ► Artikel lesen | |
| 03.06.23 | Affimed N.V.: Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan | 807 | GlobeNewswire (Europe) | Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohortAFM24 showed clinical activity in 7 out of 15 heavily pre-treated... ► Artikel lesen | |
| 03.06.23 | Allogene Therapeutics, Inc.: Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting | 490 | GlobeNewswire (Europe) | Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation... ► Artikel lesen | |
| 03.06.23 | Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting | 278 | GlobeNewswire (Europe) | - Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma... ► Artikel lesen | |
| 03.06.23 | Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting | 597 | GlobeNewswire (Europe) | ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearanceRobust... ► Artikel lesen | |
| 03.06.23 | Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 | 297 | GlobeNewswire (Europe) | Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the... ► Artikel lesen | |
| 03.06.23 | Immunocore Holdings Limited: Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO | 1.965 | GlobeNewswire (Europe) | Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3 June... ► Artikel lesen | |
| 03.06.23 | Kayne Anderson Energy Infrastructure Fund, Inc.: Kayne Anderson Energy Infrastructure Fund Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at May 31, 2023 | 375 | GlobeNewswire (Europe) | HOUSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the "Company") (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced... ► Artikel lesen | |
| 03.06.23 | Kayne Anderson NextGen Energy & Infrastructure, Inc.: Kayne Anderson NextGen Energy & Infrastructure Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at May 31, 2023 | 152 | GlobeNewswire (Europe) | HOUSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Kayne Anderson NextGen Energy & Infrastructure, Inc. (the "Fund") (NYSE: KMF) today provided a summary unaudited statement of assets and liabilities and... ► Artikel lesen | |
| 03.06.23 | Evaxion Biotech: Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial | 855 | GlobeNewswire (Europe) | The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 3.318 |
| EVOTEC | 2.652 |
| TUI | 2.089 |
| NEL | 1.333 |
| BAYER | 1.160 |
| PLUG POWER | 1.154 |
| NVIDIA | 1.153 |
| RHEINMETALL | 1.070 |
| AMC ENTERTAINMENT | 1.040 |
| DEUTSCHE BANK | 973 |
| SIEMENS ENERGY | 944 |
| RENK GROUP | 878 |
| REDCARE PHARMACY | 730 |
| COMMERZBANK | 728 |
| HEIDELBERGER DRUCK | 706 |
| ALIBABA | 689 |
| VOLKSWAGEN | 678 |
| E.ON | 621 |
| BARRICK GOLD | 615 |
| BYD | 596 |
| RWE | 590 |
| TESLA | 572 |
| DEUTSCHE LUFTHANSA | 567 |
| SIEMENS | 565 |
| AIXTRON SE | 560 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
